Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study

Richard B. Lipton, Stewart J. Tepper, Uwe Reuter, Stephen Silberstein, Walter F. Stewart, Jon Nilsen, Dean K. Leonardi, Pooja Desai, Sunfa Cheng, Daniel D. Mikol, Robert Lenz

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

OBJECTIVE: To determine the effect of erenumab, a human monoclonal antibody targeting the calcitonin gene-related peptide receptor, on health-related quality of life (HRQoL), headache impact, and disability in patients with chronic migraine (CM). METHODS: In this double-blind, placebo-controlled study, 667 adults with CM were randomized (3:2:2) to placebo or erenumab (70 or 140 mg monthly). Exploratory endpoints included migraine-specific HRQoL (Migraine-Specific Quality-of-Life Questionnaire [MSQ]), headache impact (Headache Impact Test-6 [HIT-6]), migraine-related disability (Migraine Disability Assessment [MIDAS] test), and pain interference (Patient-Reported Outcomes Measurement Information System [PROMIS] Pain Interference Scale short form 6b). RESULTS: Improvements were observed for all endpoints in both erenumab groups at month 3, with greater changes relative to placebo observed at month 1 for many outcomes. All 3 MSQ domains were improved from baseline with treatment differences for both doses exceeding minimally important differences established for MSQ-role function-restrictive (≥3.2) and MSQ-emotional functioning (≥7.5) and for MSQ-role function-preventive (≥4.5) for erenumab 140 mg. Changes from baseline in HIT-6 scores at month 3 were -5.6 for both doses vs -3.1 for placebo. MIDAS scores at month 3 improved by -19.4 days for 70 mg and -19.8 days for 140 mg vs -7.5 days for placebo. Individual-level minimally important difference was achieved by larger proportions of erenumab-treated participants than placebo for all MSQ domains and HIT-6. Lower proportions of erenumab-treated participants had MIDAS scores of severe (≥21) or very severe (≥41) or PROMIS scores ≥60 at month 3. CONCLUSIONS: Erenumab-treated patients with CM experienced clinically relevant improvements across a broad range of patient-reported outcomes. CLINICALTRIALSGOV IDENTIFIER: NCT02066415. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that for patients with CM, erenumab treatment improves HRQoL, headache impact, and disability.

Original languageEnglish (US)
Pages (from-to)e2250-e2260
JournalNeurology
Volume92
Issue number19
DOIs
StatePublished - May 7 2019

Fingerprint

Migraine Disorders
Double-Blind Method
Headache
Placebos
Quality of Life
Information Systems
Patient Reported Outcome Measures
Calcitonin Gene-Related Peptide Receptors
Pain Measurement
Monoclonal Antibodies
Pain
Therapeutics

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Lipton, R. B., Tepper, S. J., Reuter, U., Silberstein, S., Stewart, W. F., Nilsen, J., ... Lenz, R. (2019). Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study. Neurology, 92(19), e2250-e2260. https://doi.org/10.1212/WNL.0000000000007452

Erenumab in chronic migraine : Patient-reported outcomes in a randomized double-blind study. / Lipton, Richard B.; Tepper, Stewart J.; Reuter, Uwe; Silberstein, Stephen; Stewart, Walter F.; Nilsen, Jon; Leonardi, Dean K.; Desai, Pooja; Cheng, Sunfa; Mikol, Daniel D.; Lenz, Robert.

In: Neurology, Vol. 92, No. 19, 07.05.2019, p. e2250-e2260.

Research output: Contribution to journalArticle

Lipton, RB, Tepper, SJ, Reuter, U, Silberstein, S, Stewart, WF, Nilsen, J, Leonardi, DK, Desai, P, Cheng, S, Mikol, DD & Lenz, R 2019, 'Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study', Neurology, vol. 92, no. 19, pp. e2250-e2260. https://doi.org/10.1212/WNL.0000000000007452
Lipton, Richard B. ; Tepper, Stewart J. ; Reuter, Uwe ; Silberstein, Stephen ; Stewart, Walter F. ; Nilsen, Jon ; Leonardi, Dean K. ; Desai, Pooja ; Cheng, Sunfa ; Mikol, Daniel D. ; Lenz, Robert. / Erenumab in chronic migraine : Patient-reported outcomes in a randomized double-blind study. In: Neurology. 2019 ; Vol. 92, No. 19. pp. e2250-e2260.
@article{8611fa72e9cb4b9cbcfd067d5cd0bb21,
title = "Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study",
abstract = "OBJECTIVE: To determine the effect of erenumab, a human monoclonal antibody targeting the calcitonin gene-related peptide receptor, on health-related quality of life (HRQoL), headache impact, and disability in patients with chronic migraine (CM). METHODS: In this double-blind, placebo-controlled study, 667 adults with CM were randomized (3:2:2) to placebo or erenumab (70 or 140 mg monthly). Exploratory endpoints included migraine-specific HRQoL (Migraine-Specific Quality-of-Life Questionnaire [MSQ]), headache impact (Headache Impact Test-6 [HIT-6]), migraine-related disability (Migraine Disability Assessment [MIDAS] test), and pain interference (Patient-Reported Outcomes Measurement Information System [PROMIS] Pain Interference Scale short form 6b). RESULTS: Improvements were observed for all endpoints in both erenumab groups at month 3, with greater changes relative to placebo observed at month 1 for many outcomes. All 3 MSQ domains were improved from baseline with treatment differences for both doses exceeding minimally important differences established for MSQ-role function-restrictive (≥3.2) and MSQ-emotional functioning (≥7.5) and for MSQ-role function-preventive (≥4.5) for erenumab 140 mg. Changes from baseline in HIT-6 scores at month 3 were -5.6 for both doses vs -3.1 for placebo. MIDAS scores at month 3 improved by -19.4 days for 70 mg and -19.8 days for 140 mg vs -7.5 days for placebo. Individual-level minimally important difference was achieved by larger proportions of erenumab-treated participants than placebo for all MSQ domains and HIT-6. Lower proportions of erenumab-treated participants had MIDAS scores of severe (≥21) or very severe (≥41) or PROMIS scores ≥60 at month 3. CONCLUSIONS: Erenumab-treated patients with CM experienced clinically relevant improvements across a broad range of patient-reported outcomes. CLINICALTRIALSGOV IDENTIFIER: NCT02066415. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that for patients with CM, erenumab treatment improves HRQoL, headache impact, and disability.",
author = "Lipton, {Richard B.} and Tepper, {Stewart J.} and Uwe Reuter and Stephen Silberstein and Stewart, {Walter F.} and Jon Nilsen and Leonardi, {Dean K.} and Pooja Desai and Sunfa Cheng and Mikol, {Daniel D.} and Robert Lenz",
year = "2019",
month = "5",
day = "7",
doi = "10.1212/WNL.0000000000007452",
language = "English (US)",
volume = "92",
pages = "e2250--e2260",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "19",

}

TY - JOUR

T1 - Erenumab in chronic migraine

T2 - Patient-reported outcomes in a randomized double-blind study

AU - Lipton, Richard B.

AU - Tepper, Stewart J.

AU - Reuter, Uwe

AU - Silberstein, Stephen

AU - Stewart, Walter F.

AU - Nilsen, Jon

AU - Leonardi, Dean K.

AU - Desai, Pooja

AU - Cheng, Sunfa

AU - Mikol, Daniel D.

AU - Lenz, Robert

PY - 2019/5/7

Y1 - 2019/5/7

N2 - OBJECTIVE: To determine the effect of erenumab, a human monoclonal antibody targeting the calcitonin gene-related peptide receptor, on health-related quality of life (HRQoL), headache impact, and disability in patients with chronic migraine (CM). METHODS: In this double-blind, placebo-controlled study, 667 adults with CM were randomized (3:2:2) to placebo or erenumab (70 or 140 mg monthly). Exploratory endpoints included migraine-specific HRQoL (Migraine-Specific Quality-of-Life Questionnaire [MSQ]), headache impact (Headache Impact Test-6 [HIT-6]), migraine-related disability (Migraine Disability Assessment [MIDAS] test), and pain interference (Patient-Reported Outcomes Measurement Information System [PROMIS] Pain Interference Scale short form 6b). RESULTS: Improvements were observed for all endpoints in both erenumab groups at month 3, with greater changes relative to placebo observed at month 1 for many outcomes. All 3 MSQ domains were improved from baseline with treatment differences for both doses exceeding minimally important differences established for MSQ-role function-restrictive (≥3.2) and MSQ-emotional functioning (≥7.5) and for MSQ-role function-preventive (≥4.5) for erenumab 140 mg. Changes from baseline in HIT-6 scores at month 3 were -5.6 for both doses vs -3.1 for placebo. MIDAS scores at month 3 improved by -19.4 days for 70 mg and -19.8 days for 140 mg vs -7.5 days for placebo. Individual-level minimally important difference was achieved by larger proportions of erenumab-treated participants than placebo for all MSQ domains and HIT-6. Lower proportions of erenumab-treated participants had MIDAS scores of severe (≥21) or very severe (≥41) or PROMIS scores ≥60 at month 3. CONCLUSIONS: Erenumab-treated patients with CM experienced clinically relevant improvements across a broad range of patient-reported outcomes. CLINICALTRIALSGOV IDENTIFIER: NCT02066415. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that for patients with CM, erenumab treatment improves HRQoL, headache impact, and disability.

AB - OBJECTIVE: To determine the effect of erenumab, a human monoclonal antibody targeting the calcitonin gene-related peptide receptor, on health-related quality of life (HRQoL), headache impact, and disability in patients with chronic migraine (CM). METHODS: In this double-blind, placebo-controlled study, 667 adults with CM were randomized (3:2:2) to placebo or erenumab (70 or 140 mg monthly). Exploratory endpoints included migraine-specific HRQoL (Migraine-Specific Quality-of-Life Questionnaire [MSQ]), headache impact (Headache Impact Test-6 [HIT-6]), migraine-related disability (Migraine Disability Assessment [MIDAS] test), and pain interference (Patient-Reported Outcomes Measurement Information System [PROMIS] Pain Interference Scale short form 6b). RESULTS: Improvements were observed for all endpoints in both erenumab groups at month 3, with greater changes relative to placebo observed at month 1 for many outcomes. All 3 MSQ domains were improved from baseline with treatment differences for both doses exceeding minimally important differences established for MSQ-role function-restrictive (≥3.2) and MSQ-emotional functioning (≥7.5) and for MSQ-role function-preventive (≥4.5) for erenumab 140 mg. Changes from baseline in HIT-6 scores at month 3 were -5.6 for both doses vs -3.1 for placebo. MIDAS scores at month 3 improved by -19.4 days for 70 mg and -19.8 days for 140 mg vs -7.5 days for placebo. Individual-level minimally important difference was achieved by larger proportions of erenumab-treated participants than placebo for all MSQ domains and HIT-6. Lower proportions of erenumab-treated participants had MIDAS scores of severe (≥21) or very severe (≥41) or PROMIS scores ≥60 at month 3. CONCLUSIONS: Erenumab-treated patients with CM experienced clinically relevant improvements across a broad range of patient-reported outcomes. CLINICALTRIALSGOV IDENTIFIER: NCT02066415. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that for patients with CM, erenumab treatment improves HRQoL, headache impact, and disability.

UR - http://www.scopus.com/inward/record.url?scp=85065680853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065680853&partnerID=8YFLogxK

U2 - 10.1212/WNL.0000000000007452

DO - 10.1212/WNL.0000000000007452

M3 - Article

C2 - 30996060

AN - SCOPUS:85065680853

VL - 92

SP - e2250-e2260

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 19

ER -